One-lung ventilation patients: Clinical context of administration of different doses of dexmedetomidine

Hui Jiang, Yu Kang, Chunlin Ge, Zhenying Zhang, Yan Xie, Hui Jiang, Yu Kang, Chunlin Ge, Zhenying Zhang, Yan Xie

Abstract

Background: Open and endoscopic thoracic surgeries improve surgical exposure by One-lung ventilation (OLV). The aim of this study was to investigate the effects of different doses of dexmedetomidine on inflammatory response, oxidative stress, cerebral tissue oxygen saturation (SctO2) and intrapulmonary shunt in patients undergoing one-lung ventilation (OLV).

Methods: Seventy-five patients undergoing open pulmonary lobectomy in our hospital from January 2016 to December 2017 were enrolled and randomly divided into high-dose dexmedetomidine group (group D1, 1 mg/kg, n=25), low-dose dexmedetomidine group (group D2, 0.5 mg/kg, n=25) and control group (group C, n=25). Then, arterial blood and internal jugular venous blood were taken before anesthesia induction (T0) and at 15 min after twolung ventilation (T1) and 5 min (T2) and 30 min (T3) after OLV for later use. Next, the changes in hemodynamic parameters [mean arterial pressure (MAP), heart rate (HR) and pulse oxygen saturation (SpO2)] of patients were observed in each group. Enzyme-linked immunosorbent assay (ELISA) was carried out to detect serum inflammatory factors such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) and oxidative stress indicators [superoxide dismutase (SOD) and malondialdehyde (MDA)]. The changes in SctO2, arterial partial pressure of oxygen (PaO2) and intrapulmonary shunt Qs/Qt (a measurement of pulmonary shunt: right-to-left shunt fraction) were observed. Additionally, the changes in lung function indicators like lung dynamic compliance (Cdyn) and airway peak pressure (Ppeak) were determined.

Results: There were no statistically significant differences in the MAP, HR and SpO2 among three groups at each observation time point (P>0.05). At T2 and T3, the levels of serum IL-6, TNF-α and IL-8 were obviously decreased in group D1 and D2 compared with those in group C (P<0.05), and the decreases in group D1 were overtly larger than those in group D2, and the decreases at T3 were markedly greater than those at T2 (P<0.05). In comparison with group C, group D1 and D2 had notably reduced levels of serum reactive oxygen species (ROS) and MDA (P<0.05) and remarkably increased SOD content (P<0.05) at T2 and T3, and the effects were markedly better in group D1 than those in group D2. Besides, they were significantly superior at T3 to those at T2 (P<0.05). The SctO2 in group D1 and D2 was evidently lowered at T2 and T3 compared with that at T0, and the decrease in group D1 was distinctly smaller than that in group D2 (P<0.05). The Qs/Qt was significantly lower in group D1 and D2 than that in group C at T2 and T3 (P<0.05), while the PaO2 content was notably raised (P<0.05), and the decrease and increase were significantly larger in group D1 than those in group D2, and they were obviously greater at T3 to those at T2 (P<0.05). At T0 and T1, no significant differences were detected in the Cdyn, Pplat and Ppeak among three groups. At T2 and T3, the Cdyn was significantly elevated, while the Pplat and Ppeak overtly declined (P<0.05), and group D1 had greater changes in comparison with group D2, and the changes were obviously more evident at T3 to those at T2 (P<0.05).

Conclusions: Dexmedetomidine effectively ameliorates inflammatory response and oxidative stress, lowers oxygenation, Qs/Qt and the decrease in SctO2 and improves lung function during OLV, with good efficacy.

Keywords: cerebral tissue oxygen saturation; dexmedetomidine; inflammatory response; intrapulmonary shunt; one-lung ventilation; oxidative stress.

Conflict of interest statement

Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.

2022 Hui Jiang, Yu Kang, Chunlin Ge, Zhenying Zhang, Yan Xie, published by CEON/CEES.

References

    1. 1. Karzai W, Schwarzkopf K. Hypoxemia During One-Lung Ventilation: Prediction, Prevention, and Treatment. Anesthesiology. 2009;110(6):1402.
    1. 2. Pan W Z, Du J, Zhang L Y, Ma J H. The Roles of NF-kB in the Development of Lung Injury After One-Lung Ventilation. Eur Rev Med Pharmacol Sci. 2018;22(21):7414.
    1. 3. Garutti I, Cruz P, Olmedilla L, Barrio J M, Cruz A, Fernandez C, et al. Effects of Thoracic Epidural Meperidine on Arterial Oxygenation During One-Lung Ventilation in Thoracic Surgery. J Cardiothorac Vasc Anesth. 2003;17(3):302. doi: 10.1016/s1053-0770(03)00056-9.
    1. 4. Jung S M, Cho C K, Kim Y J, Cho H M, Kim C J, Kwon H U, et al. The Effect of Thoracic Epidural Anesthesia on Pulmonary Shunt Fraction and Arterial Oxygenation During One-Lung Ventilation. J Cardiothorac Vasc Anesth. 2010;24(3):456. doi: 10.1053/j.jvca.2009.09.011.
    1. 5. Kocoglu H, Ozturk H, Ozturk H, Yilmaz F, Gulcu N. Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Rat Kidney: A Histopathologic Study. Ren Fail. 2009;31(1):70. doi: 10.1080/08860220802546487.
    1. 6. Yagmurdur H, Ozcan N, Dokumaci F, Kilinc K, Yilmaz F, Basar H. Dexmedetomidine Reduces the Ischemia-Reperfusion Injury Markers During Upper Extremity Surgery With Tourniquet. J Hand Surg Am. 2008;33(6):941. doi: 10.1016/j.jhsa.2008.01.014.
    1. 7. Koroglu A, Demirbilek S, Teksan H, Sagır O, But A K, Ersoy M O. Sedative, Haemodynamic and Respiratory Effects of Dexmedetomidine in Children Undergoing Magnetic Resonance Imaging Examination: Preliminary Results. Br J Anaesth. 2005;94(6):821. doi: 10.1093/bja/aei119.
    1. 8. Arain S R, Ruehlow R E M, Uhrich T D, Ebert T J. The Efficacy of Dexmedetomidine Versus Morphine for Postoperative Analgesia After Major Inpatient Surgery. Anesth Analg. 2004;98(1):153. doi: 10.1213/01.ane.0000093225.39866.75.
    1. 9. Shen J, Fu G, Jiang L, Xu J, Li L I, Fu G. Effect of Dexmedetomidine Pretreatment on Lung Injury Following Intestinal Ischemia-Reperfusion. Exp Ther Med. 2013;6(6):1359. doi: 10.3892/etm.2013.1317.
    1. 10. Chen Z, Ding T, Ma C G. Dexmedetomidine (DEX) Protects Against Hepatic Ischemia/Reperfusion (I/R) Injury by Suppressing Inflammation and Oxidative Stress in NLRC5 Deficient Mice. Biochem Biophys Res Commun. 2017;493(2):1143.
    1. 11. Saifi H, Mabrouk Y, Saifi R, Benabdelkader M, Saidi M. Influence of selenium supplementation on carbohydrate metabolism and oxidative stress in pregnant women with gestational diabetes mellitus. J Med Biochem. 2020;39(2):191.
    1. 12. Kentner R, Safar P, Behringer W, Wu X, Kagan V E, Tyurina Y Y, et al. Early Antioxidant Therapy with Tempol During Hemorrhagic Shock Increases Survival in Rats. J Trauma. 2002;53(5):968.
    1. 13. Murkin J M, Arango M. Near-Infrared Spectroscopy as an Index of Brain and Tissue Oxygenation. Br J Anaesth. 2009;103(Suppl 1):i3. doi: 10.1093/bja/aep299.
    1. 14. Rodríguez-Roisin R, Drakulovic M, Rodríguez D A, Roca J, Barberà J A, Wagner P D. Ventilation-Perfusion Imbalance and Chronic Obstructive Pulmonary Disease Staging Severity. J Appl Physiol (1985) 2009;106(6):1902. doi: 10.1152/japplphysiol.00085.2009.
    1. 15. Viegas M, Diaz-Castrillon C E, Castro-Medina M, da Fonseca D S L, Morell V O. Bidirectional Glenn Procedure in Patients Less Than 3 Months of Age: A 14-Year Experience. Ann Thorac Surg. 2020;110(2):622. doi: 10.1016/j.athoracsur.2020.03.080.
    1. 16. Lumb A B, Slinger P. Hypoxic Pulmonary Vasoconstriction: Physiology and Anesthetic Implications. Anesthesiology. 2015;122:932–946.
    1. 17. Groeben H, Mitzner W, Brown R H. Effects of the alpha2-Adrenoceptor Agonist Dexmedetomidine on Bronchoconstriction in Dogs. Anesthesiology. 2004;100(2):359. doi: 10.1097/00000542-200402000-00026.
    1. 18. Xia R, Yin H, Xia Z, Mao Q J, Chen G D, Xu W. Effect of Intravenous Infusion of Dexmedetomidine Combined with Inhalation of Isoflurane on Arterial Oxygenation and Intrapulmonary Shunt During Single-Lung Ventilation. Cell Biochem Biophys. 2013;67(3):1547. doi: 10.1007/s12013-013-9659-8.
    1. 19. Unal Y, Pampal H K, Arslan M, Demirel C B, Alkan M. The Effects of Dexmedetomidine on Pulmonary Artery Pressure in Experiment. Bratisl Lek Listy. 2014;115(5):272. doi: 10.4149/bll_2014_056.
    1. 20. Vickovic S, Pjevic M, Uvelin A, Pap D, Nikolic D, Lalic I. Magnesium Sulfate as an Adjuvant to Anesthesia in Patients with Arterial Hypertension. Acta Clin Croat. 2016;55(3):490. doi: 10.20471/acc.2016.55.03.20.
    1. 21. Čolak E, Pap D, Nikolić L, Vicković S. The impact of obesity to antioxidant defense parameters in adolescents with increased cardiovascular risk. J Med Biochem. 2020;39(3):346. doi: 10.2478/jomb-2019-0051.
    1. 22. Čolak E, Pap D. The role of oxidative stress in the development of obesity and obesity-related metabolic disorders. J Med Biochem. 2021;40(1):1. doi: 10.5937/jomb0-24652.
    1. 23. Zhao L, An R, Yang Y, Yang X, Liu H, Yue L, et al. Melatonin Alleviates Brain Injury in Mice Subjected to Cecal Ligation and Puncture Via Attenuating Inflammation, Apoptosis, and Oxidative Stress: The Role of Sirt1 Signaling. J Pineal Res. 2015;59(2):230. doi: 10.1111/jpi.12254.
    1. 24. Casati A, Fanelli G, Pietropaoli P, Proietti R, Tufano R, Danelli G, et al. Continuous Monitoring of Cerebral Oxygen Saturation in Elderly Patients Undergoing Major Abdominal Surgery Minimizes Brain Exposure to Potential Hypoxia. Anesth Analg. 2005;101(3):740. doi: 10.1213/.
    1. 25. Shahi V, Verma A K, Agarwal A, Singh C S. A Comparative Study of Magnesium Sulfate Vs Dexmedetomidine as an Adjunct to Epidural Bupivacaine. J Anaesthesiol Clin Pharmacol. 2014;30(4):538. doi: 10.4103/0970-9185.142852.
    1. 26. Kästner S B R, Kull S, Kutter A P N, Boller J, Bettschart-Wolfensberger R, Huhtinen M K. Cardiopulmonary Effects of Dexmedetomidine in Sevoflurane-Anesthetized Sheep with and Without Nitric Oxide Inhalation. Am J Vet Res. 2005;66(9):1496. doi: 10.2460/ajvr.2005.66.1496.
    1. 27. Elhakim M, Abdelhamid D, Abdelfattach H, Magdy H, Elsayed A, Elshafei M. Effect of Epidural Dexmedetomidine on IntraOperative Awareness and Post-Operative Pain After One-Lung Ventilation. Acta Anaesthesiol Scand. 2010;54(6):703. doi: 10.1111/j.1399-6576.2009.02199.x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe